# A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

> **NCT04847102** · PHASE3 · UNKNOWN · sponsor: **Walvax Biotechnology Co., Ltd.** · enrollment: 28000 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 mRNA Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04847102
- **Lead sponsor:** Walvax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-22
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 28000 (ESTIMATED)
- **Last updated:** 2021-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847102, "A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04847102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*